Format

Send to

Choose Destination

Links from PubMed

F1000Res. 2019 Aug 7;8. pii: F1000 Faculty Rev-1371. doi: 10.12688/f1000research.19509.1. eCollection 2019.

Emerging therapies against infections with Pseudomonas aeruginosa.

Author information

1
Clinical Research Group 'Molecular Pathology of Cystic Fibrosis' and 'Pseudomonas Genomics', Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, 30625, Germany.
2
Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center of Lung Disease, Hannover, 30625, Germany.
3
Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, 30625, Germany.

Abstract

Infections with Pseudomonas aeruginosa have been marked with the highest priority for surveillance and epidemiological research on the basis of parameters such as incidence, case fatality rates, chronicity of illness, available options for prevention and treatment, health-care utilization, and societal impact. P. aeruginosa is one of the six ESKAPE pathogens that are the major cause of nosocomial infections and are a global threat because of their capacity to become increasingly resistant to all available antibiotics. This review reports on current pre-clinical and clinical advances of anti-pseudomonal therapies in the fields of drug development, antimicrobial chemotherapy, vaccines, phage therapy, non-bactericidal pathoblockers, outer membrane sensitizers, and host defense reinforcement.

KEYWORDS:

Pseudomonas aeruginosa; antibiotic; phage therapy; vaccine; ß-lactam inhibitor

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Publication type

Publication type

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center